IBM Retirement Fund increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 136.8% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 12,031 shares of the company’s stock after buying an additional 6,950 shares during the period. IBM Retirement Fund’s holdings in Zoetis were worth $838,000 as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in ZTS. Assetmark Inc. boosted its stake in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after buying an additional 85 shares during the period. Guardian Life Insurance Co. of America boosted its stake in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares during the period. Point72 Asia Hong Kong Ltd bought a new stake in shares of Zoetis during the first quarter worth approximately $111,000. Advisory Services Network LLC bought a new stake in shares of Zoetis during the first quarter worth approximately $112,000. Finally, First Interstate Bank boosted its stake in shares of Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares during the period. Hedge funds and other institutional investors own 92.70% of the company’s stock.
Zoetis Inc. (NYSE:ZTS) opened at 60.75 on Friday. The company has a 50-day moving average price of $61.95 and a 200-day moving average price of $58.24. The firm has a market cap of $29.71 billion, a PE ratio of 34.34 and a beta of 1.02. Zoetis Inc. has a one year low of $46.86 and a one year high of $63.85.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting the consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the previous year, the company posted $0.49 EPS. Zoetis’s revenue was up 5.0% on a year-over-year basis. Equities analysts predict that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “IBM Retirement Fund Acquires 6,950 Shares of Zoetis Inc. (NYSE:ZTS)” was originally published by BNB Daily and is owned by of BNB Daily. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/zoetis-inc-nysezts-shares-bought-by-ibm-retirement-fund-updated-updated.html.
A number of equities research analysts have commented on ZTS shares. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $67.00 target price on the stock in a report on Wednesday, May 10th. Jefferies Group LLC increased their target price on Zoetis from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, May 9th. BMO Capital Markets reiterated a “buy” rating and set a $60.00 target price on shares of Zoetis in a report on Thursday, May 4th. Argus reiterated a “buy” rating and set a $69.00 target price (up previously from $60.00) on shares of Zoetis in a report on Tuesday, May 30th. Finally, CL King started coverage on Zoetis in a report on Friday, May 26th. They set a “buy” rating and a $71.00 price objective on the stock. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus target price of $64.78.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.